サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363133

薬物動態サービスの市場規模、シェア、動向分析レポート：薬剤タイプ別、用途別、最終用途別、地域別、セグメント別予測、2023年～2030年

Pharmacokinetics Services Market Size, Share & Trends Analysis Report By Drug Type (Small Molecules), By Application (SMEs) By End-use (Biotechnology & Pharmaceutical Companies) By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 110 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
薬物動態サービスの市場規模、シェア、動向分析レポート：薬剤タイプ別、用途別、最終用途別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月22日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

薬物動態サービス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の薬物動態サービス市場規模は、2023年から2030年にかけてCAGR 7.5%を記録し、2030年までに17億6,240万米ドルに達する見込みです。

無観察効果レベル（NOEL）、ヒト等価用量（HED）レベル、薬物動態学/薬力学（PK/PD） 促進要因など、いくつかのパラメータを決定するための薬物動態学および毒物学研究の採用が増加しており、市場成長を促進すると予想されます。

潜在的な医薬品候補の薬物動態プロファイルを十分に理解することは、創薬プログラムの成功に大きな役割を果たします。これに加え、規制機関はPK試験の実施に関する明確なガイドラインを制定することで、この市場の進展に大きな役割を果たしています。関連するEMEA、ICH、FDA、GCP、その他の規制ガイドラインに従ってPK試験を実施するCROが相当数存在します。

医薬品開発プロセスにおけるPKサービスの効果的な実施に対する関心の高まりは、この分野への投資を促進すると予想されます。臨床および前臨床の医薬品開発における薬物動態の応用に関連するさまざまなパラダイムに対する理解を深めるために、世界中でいくつかの会議や認定コースが実施されています。

薬物動態サービス市場レポートハイライト

  • 薬剤タイプ別では、低分子が2022年の収益シェア76.7%で市場を独占し、予測期間中もサービスの高い普及率とジェネリック医薬品の人気の高まりに後押しされてリードを維持すると予想されます。
  • 高分子のPK解析は、臨床開発段階にある多数の生物製剤とバイオシミラーの存在によって、予測期間中に大きく成長する見込みです。
  • 米国には多数のバイオ医薬品および医薬品製造事業体が存在するため、2022年には北米が最大のシェアを占めることになります。
  • アジア太平洋地域は、予測期間中最も速いCAGR 9.2%で拡大すると予測されます。これは、いくつかの国々における絶え間ない経済成長により、世界のCROから大きな注目を集め、事業拡大につながったためです。
  • Pharmaceutical Product Development, LLC、Charles River Laboratories International, Inc.、PAREXEL International Corporation、Eurofins Scientific, Inc.などが主なサービスプロバイダーです。
  • これらのCROは、新たな市場の道を開拓し、将来の市場でのシェアを高めるため、様々な取り組みを行っています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 薬物動態サービス市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 薬物動態サービス市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 薬物動態サービス市場：薬剤タイプ別推定・動向分析

  • 薬物動態サービス市場、重要なポイント
  • 薬物動態サービス市場：動向と市場シェア分析、2022年および2030年
  • 低分子
  • 高分子（バイオ医薬品）

第5章 薬物動態サービス市場：用途別推定・動向分析

  • 薬物動態サービス市場、重要なポイント
  • 薬物動態サービス市場：動向と市場シェア分析、2022年および2030年
  • 中小企業
  • 大企業

第6章 薬物動態サービス市場： 最終用途別推定・動向分析

  • 薬物動態サービス市場、重要なポイント
  • 薬物動態サービス市場：動向と市場シェア分析、2022年および2030年
  • バイオテクノロジーおよび製薬会社
  • 学術および政府の研究機関
  • その他

第7章 薬物動態サービス市場：地域別推定・動向分析

  • 地域別の見通し
  • 地域別の薬物動態サービス市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Evotec AG
    • Certara, L.P.
    • Pacific BioLabs
    • GVK Biosciences Private Limited
    • Shanghai Medicilon Inc.
    • Pharmaceutical Product Development, LLC
    • Charles River Laboratories International, Inc.
    • PAREXEL International Corporation
    • Eurofins Scientific, Inc.
    • Frontage Labs
    • SGS SA
    • LGC Limited
    • Creative Bioarray
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 3 North America pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 5 North America pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S. pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 7 U.S. pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S. pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 10 Canada pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 13 Europe pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 14 Europe pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 17 Germany pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 20 UK pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 21 UK pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 23 France pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 24 France pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 26 Italy pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 29 Spain pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 32 Denmark pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 35 Sweden pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 38 Norway pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 44 Japan pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 45 Japan pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 46 Japan pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 48 China pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 49 China pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 51 India pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 52 India pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 53 Australia pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 54 Australia pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 55 Australia pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Thailand pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 57 Thailand pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 58 Thailand pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 59 South Korea pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 60 South Korea pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 61 South Korea pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 63 Latin America pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 64 Latin America pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 67 Brazil pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 70 Mexico pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 73 Argentina pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa pharmacokinetic services market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 80 South Africa pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 86 UAE pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait pharmacokinetic services market, by drug type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait pharmacokinetic services market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait pharmacokinetic services market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Pharmacokinetic services: Market outlook
  • Fig. 9 Pharmacokinetic services Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Pharmacokinetic services market driver impact
  • Fig. 15 Pharmacokinetic services market restraint impact
  • Fig. 16 Pharmacokinetic services market strategic initiatives analysis
  • Fig. 17 Pharmacokinetic services market: Drug type movement analysis
  • Fig. 18 Pharmacokinetic services market: Drug type outlook and key takeaways
  • Fig. 19 Small molecules market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Large molecules (biopharmaceuticals) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Pharmacokinetic services market: Application movement analysis
  • Fig. 22 Pharmacokinetic services market: Application outlook and key takeaways
  • Fig. 23 Small and medium enterprise market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Large enterprise market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Pharmacokinetic services market: End use movement analysis
  • Fig. 26 Pharmacokinetic services market: End use outlook and key takeaways
  • Fig. 27 Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Academic & government research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Global pharmacokinetic services market: Regional movement analysis
  • Fig. 31 Global pharmacokinetic services market: Regional outlook and key takeaways
  • Fig. 32 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-2-68038-375-1

Pharmacokinetics Services Market Growth & Trends:

The global pharmacokinetics services market size is expected to reach USD 1,762.4 million by 2030, registering a CAGR of 7.5% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising adoption of pharmacokinetic and toxicology studies for determination of several parameters such as no-observed-effect levels (NOEL), human equivalent doses (HED) levels, and pharmacokinetic/pharmacodynamic (PK/PD) drivers are expected to fuel market growth.

Thorough understanding of the pharmacokinetic profile of a potential drug candidate plays a major role in the success of a drug discovery program. In addition to this, regulatory bodies have played a major role in the progress of this market through establishing defined guidelines for conducting PK studies. There are a substantial number of CROs engaged in conducting PK studies in accordance with relevant EMEA, ICH, FDA, GCP, and other regulatory guidelines.

Growing concern for effective implementation of PK services in the drug development process is anticipated to drive investments in this sector. Several conferences and certification courses are being conducted across the world to increase the understanding of various paradigms associated with pharmacokinetics application in clinical and preclinical drug development.

Pharmacokinetics Services Market Report Highlights:

  • Based on drug type, Small molecule dominated the market with a revenue share of 76.7% in 2022 and is expected to maintain its lead during the forecast period fueled by high service penetration and growing popularity of generics
  • PK analysis for large molecules are expected to grow significantly during the forecast period, driven by presence of significant number of biologics and biosimilars in the clinical development phase
  • Presence of a large number of biopharmaceutical and pharmaceutical manufacturing entities in U.S. has resulted in North America accounting for the largest share in 2022
  • Asia Pacific is estimated to expand at the fastest CAGR of 9.2% over the forecast period thanks to constant economic growth in several countries, which has attracted significant attention from global CROs and resulted in business expansions
  • Pharmaceutical Product Development, LLC; Charles River Laboratories International, Inc.; PAREXEL International Corporation; and Eurofins Scientific, Inc. are some of the key service providers
  • These CROs are undertaking various initiatives in order to capitalize on new market avenues and enhance their share in the future market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Type
    • 1.1.2. Application
    • 1.1.3. End use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Type outlook
    • 2.2.2. Application outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Pharmacokinetic Services Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Pharmacokinetic Services Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Pharmacokinetic Services Market: Drug Type Estimates & Trend Analysis

  • 4.1. Pharmacokinetic Services Market, Key Takeaways
  • 4.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Small Molecule
    • 4.3.1. Small molecule market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Large Molecules (Biopharmaceuticals)
    • 4.4.1. Large molecule (biopharmaceuticals) market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Pharmacokinetic Services Market: Application Estimates & Trend Analysis

  • 5.1. Pharmacokinetic Services Market, Key Takeaways
  • 5.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Small and Medium Enterprise
    • 5.3.1. Small and medium enterprise market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Large Enterprise
    • 5.4.1. Large enterprise market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Pharmacokinetic Services Market: End Use Estimates & Trend Analysis

  • 6.1. Pharmacokinetic Services Market, Key Takeaways
  • 6.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Biotechnology & Pharmaceutical Companies
    • 6.3.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Academic & Government Research Institutes
    • 6.4.1. Academic & government research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Pharmacokinetic Services Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Pharmacokinetic Services Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.6. Denmark
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.4.8. Norway
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Evotec AG
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Certara, L.P.
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Pacific BioLabs
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. GVK Biosciences Private Limited
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Shanghai Medicilon Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Pharmaceutical Product Development, LLC
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Charles River Laboratories International, Inc.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. PAREXEL International Corporation
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Eurofins Scientific, Inc.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Frontage Labs
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. SGS SA
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. LGC Limited
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives
    • 8.2.13. Creative Bioarray
      • 8.2.13.1. Company overview
      • 8.2.13.2. Financial performance
      • 8.2.13.3. Product benchmarking
      • 8.2.13.4. Strategic initiatives